AMYLYX PHARMACEUTICALS INC (AMLX) Stock Balance Sheet
NASDAQ:AMLX - Nasdaq - US03237H1014 - Common Stock - Currency: USD
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 71.84M | 170.20M | 62.50M | 50.20M | 12.90M | |||
| Marketable Securities | 162.56M | 201.16M | 284.40M | 45.90M | N/A | |||
| Receivables | 1.73M | 40.05M | 15.30M | N/A | N/A | |||
| Inventories | 0.00 | 38.32M | 9.80M | N/A | N/A | |||
| Other Current Assets | 9.14M | 14.93M | 10.10M | 8.80M | 800.00K | |||
| Total Current Assets | 245.26M | 464.67M | 382.10M | 105.00M | 13.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 3.53M | 6.41M | 8.10M | 500.00K | 200.00K | |||
| Other Non-Current Assets | 1.92M | 46.38M | 1.20M | 200.00K | 300.00K | |||
| Total Non-Current Assets | 5.45M | 52.79M | 9.40M | 600.00K | 500.00K | |||
| TOTAL ASSETS | 250.71M | 517.45M | 391.50M | 105.60M | 14.10M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | 0.00 | N/A | |||
| Accrued Expenses | 52.43M | 59.98M | 40.40M | 13.00M | 3.70M | |||
| Accounts Payable | 1.49M | 22.06M | 6.30M | 4.40M | 3.60M | |||
| Other Current Liabilities | N/A | N/A | N/A | 17.40M | N/A | |||
| Total Current Liabilities | 53.91M | 82.04M | 46.60M | 17.40M | 7.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | |||
| Other Non-Current Liabilities | 595.00K | 1.98M | 4.20M | 0.00 | 1.20M | |||
| Total Non-Current Liabilities | 595.00K | 1.98M | 4.20M | 0.00 | 1.50M | |||
| TOTAL LIABILITIES | 54.51M | 84.02M | 50.80M | 17.40M | 8.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -569.15M | -304.95M | -354.20M | -155.80M | -67.90M | |||
| Additional Paid In Capital | 764.70M | 738.18M | 694.90M | 4.70M | 1.20M | |||
| Common Shares | 7.00K | 7.00K | 0.00 | 239.40M | 72.10M | |||
| Other Shareholders' Equity | 641.00K | 197.00K | -100.00K | 0.00 | N/A | |||
| Shares Outstanding | 68.55M | 67.71M | 66.50M | 56.50M | 56.50M | |||
| Tangible Book Value per Share | 2.86 | 6.40 | 5.12 | -2.68 | -1.18 | |||
| Total Shareholders' Equity | 196.20M | 433.43M | 340.60M | 88.20M | 5.30M | |||
| TOTAL LIABILITIES AND EQUITY | 250.71M | 517.45M | 391.50M | 105.60M | 14.10M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | 0.06 | |||
| Current Ratio | 4.55 | 5.66 | 8.20 | 6.03 | 1.86 | |||
| Return On Assets (ROA) | -103.49% | 9.52% | -50.67% | -83.27% | -299.86% | |||
| Return On Equity (ROE) | -132.24% | 11.37% | -58.24% | -99.69% | -797.74% | |||
| Return On Invested Capital (ROIC) | N/A | 7.04% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | 47.86% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | 47.86% | N/A | N/A | N/A | |||
All data in USD , ROIC based on taxRate of 0.21